Dihexa (sometimes written "digexa") is one of the loudest research compounds in the cognition space. It draws bold claims about "growing new synapses" and sharp memory gains. Some of that rests on real experiments, some on loose retellings of them. Let us go through what the molecule is, how it works according to the available data, and where the line runs between proven and hoped for.
What Dihexa is
Dihexa is a synthetic oligopeptide, a derivative of angiotensin IV (Ang IV). It was developed at Washington State University by a group studying the role of the angiotensin system in learning and memory. If you want a basic explanation of what peptides are and how they differ from proteins, it is in a separate piece, what peptides are in plain words.
Two properties made Dihexa notable. First, in rodent studies it turned out to be orally active and able to cross the blood-brain barrier, which is unusual for a peptide. Second, in some assays its activity in potentiating the relevant signal was very high, orders of magnitude greater than angiotensin IV itself.
Mechanism: HGF/c-Met and synaptogenesis
The main mechanistic hypothesis is tied not to angiotensin receptors directly but to the hepatocyte growth factor (HGF) system and its receptor c-Met. Dihexa is thought to potentiate this system, which in turn is involved in the formation of new synapses (synaptogenesis). In neuronal cultures and animal models this showed up as additional synaptic contacts and better learning scores.
It sounds striking, but a caveat is needed. Boosting a growth-factor signal is a double-edged thing: the same biology that builds synapses is, in a wider context, linked to cell growth and division. That is one reason such molecules are treated cautiously at the systemic level, and why their place for now is in the lab, not the pharmacy.
What the studies showed
The available evidence is mostly preclinical. In rodents Dihexa improved learning and memory in models of cognitive deficit, including one induced by blocking cholinergic transmission, and it was also studied in the context of age-related changes and Parkinson's models. The results in these models were encouraging precisely as a signal for further study.
What is missing: published controlled clinical trials in humans. That means the efficacy and, above all, the safety of Dihexa in people are not established. The dosages circulating online come from extrapolating animal data, not from clinical protocols. For a compound that works through a growth factor, that is not a small detail.
Dihexa among nootropic peptides
Context helps. We put together a general overview of the field in nootropic peptides. Compared with Dihexa, some neighbors have a far fuller study history. Semax has decades of use and clinical work in its region; Selank was studied as an anxiolytic. This does not make Dihexa "worse," but it illustrates the difference between an interesting preclinical molecule and a compound with real human data.
It is important not to confuse Dihexa with peptide "mixtures" like cerebrolysin. We wrote about that difference in the review cerebrolysin and peptide analogs: Dihexa is one defined molecule with a known structure, not a hydrolysate of complex and variable composition.
Purity, identity, and how it is handled
Dihexa is niche and potent at its target, so the question of "what exactly is in the vial" is not a formality here. Without confirmed identity it is easy to mix up the compound or end up with material of unknown purity, and then any result becomes impossible to interpret correctly. A correct experiment needs material of known composition with a certificate of analysis (COA) per batch. Why that matters more than a low price we explained in the piece on research use and the COA; you can check a batch on the verification page. If you are after better-characterized nootropic peptides, look at the Semax and Selank pages.
Use context
Everything described concerns research use only. It is not medical advice, and Dihexa is not positioned as something that treats a condition or reliably improves memory. Given the absence of clinical data and the growth-factor mechanism, it is reasonable to treat this compound as an object of study. Your own health is a question for a doctor, not for a blog overview.
Disclaimer. This material is informational and intended for research purposes. Longeva supplies peptides as research substances with an independent COA for every batch.